An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)

BACKGROUND: Chemotherapy added to anti-HER2 agents (H) is the treatment of choice in patients with HER2+ early breast cancer. However, HER2+ tumours are clinically and biologically heterogeneous, and treatment response varies significantly by hormone receptor (HR) status and molecular subtype. Predi...

Descripción completa

Detalles Bibliográficos
Autores principales: Risi, Emanuela, Biagioni, Chiara, Benelli, Matteo, Migliaccio, Ilenia, McCartney, Amelia, Bonechi, Martina, Guarducci, Cristina, Hilbers, Florentine, Di Cosimo, Serena, Huober, Jens, Romagnoli, Dario, Boccalini, Giulia, Vitale, Stefania, Sotiriou, Christos, Biganzoli, Laura, Di Leo, Angelo, Malorni, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906346/
https://www.ncbi.nlm.nih.gov/pubmed/31853266
http://dx.doi.org/10.1177/1758835919891608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906346/
https://www.ncbi.nlm.nih.gov/pubmed/31853266
http://dx.doi.org/10.1177/1758835919891608

Ejemplares similares